About: Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 14 February 2018

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) scientific article published on 14 February 2018 (en) article scientifique publié en 2018 (fr) artículu científicu espublizáu en febreru de 2018 (ast) наукова стаття, опублікована 14 лютого 2018 (uk)
publication date	wds:Q90005545-FFEDF1C1-2023-46E3-A20B-AB8289B54982
publication date	2018-02-14 00:00:00Z (xsd:dateTime)
cites work	wds:Q90005545-00DD2C4B-BE9F-4A45-8345-92158FC85ABE wds:Q90005545-033FE3E8-ED22-4D1E-8DA4-B06617380F25 wds:Q90005545-0423827F-3C88-4370-86EB-3F2CED2C9391 wds:Q90005545-2589C8F2-24CE-42C3-8CDC-3226027458AB wds:Q90005545-2BAEA548-F801-4D8E-BB6F-503852FB2319 wds:Q90005545-305BD83D-0941-4944-B0BA-3C05B4774DAC wds:Q90005545-3311776E-B057-47EC-9D04-5889CCE3C955 wds:Q90005545-3E217D5A-B964-4DCA-920F-1D48BDD13161 wds:Q90005545-4E0E5D76-1BDE-4F13-9AA1-A4EA604702B0 wds:Q90005545-56A4372D-6E13-455B-9A20-A08C0D2E5FC1 wds:Q90005545-5D7B1F7E-89EF-47A7-8007-C3F571D4F27E wds:Q90005545-6122672F-700C-42B6-9885-20C21EBA4769 wds:Q90005545-638B75CB-5E0E-4A76-BE14-0FD82165A4B7 wds:Q90005545-742FFFD3-DF2F-4A7C-959A-DD513C5BD924 wds:Q90005545-79D5E790-6AD8-435B-97EA-F86E20FCCA2E wds:Q90005545-8B459E35-981D-4F4D-8A89-70724B2847D0 wds:Q90005545-8C612E9E-AC9D-4D7F-95E3-0B63D3041CE4 wds:Q90005545-8D117495-076F-4C62-A658-4CCDFF92C4CE wds:Q90005545-9397E8DB-FAD2-482C-9086-6BE9A7B30953 wds:Q90005545-96FB1CD5-3EBE-4187-BC18-0E44D8CE0018 wds:Q90005545-A78CDA9A-D4A5-4225-B08C-901A8A205E6F wds:Q90005545-ACEE7804-D6B9-4979-BF8D-15D56B446B6B wds:Q90005545-B6FDA549-43A9-4647-8FC3-94F196FB50C4 wds:Q90005545-C0C2B4F3-C15A-4658-BC9E-1AABD6A8C531 wds:Q90005545-C5B07848-64E8-4B0C-993C-BC531D9EF8EB wds:Q90005545-DA750A79-B515-41B5-AFC3-4C4E4035E1B6 wds:Q90005545-ED730E4B-D045-472F-B067-CAF4F386CAC8 wds:Q90005545-F3FC700B-E8B9-4E80-81D2-CEF5817B35D1
cites work	Identification of the breast cancer susceptibility gene BRCA2 Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Resistance to therapy caused by intragenic deletion in BRCA2 Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy (ADP-ribose)n participates in DNA excision repair Secondary mutations of BRCA1/2 and drug resistance Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2 Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13 Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer PARP inhibitors: Synthetic lethality in the clinic Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. DNA-Repair Gene Mutations in Metastatic Prostate Cancer
author name string	wds:Q90005545-04021959-89C7-446A-9196-5E3E6C817126 wds:Q90005545-0E18439B-A1FB-450A-824C-50746641E8D0 wds:Q90005545-30BEE2BE-91AC-40ED-BFE8-3F0068E31D2C wds:Q90005545-4D16AE34-A5C3-46D8-981D-EDBF10382D83 wds:Q90005545-4F38EAF9-6B07-4C9B-951E-9E20986538A1 wds:Q90005545-5979631F-5F85-40CC-9BBF-CFEDDC258653 wds:Q90005545-6B43E146-2421-46E0-91D7-1525C321EDCD wds:Q90005545-7D461F2A-58AB-4F92-B1EE-564578A5D2E6 wds:Q90005545-85E0C0D1-761B-494E-A32F-3A9E206BA2E6 wds:Q90005545-8E7E18D3-46DC-45F3-9941-530C63D68073 wds:Q90005545-9145862D-66B9-4D44-8A59-568612EE0A2C wds:Q90005545-988DF0EE-AB0E-4613-A4A9-961250737202 wds:Q90005545-AB86EB36-034C-4494-BC92-A801599C5D73 wds:Q90005545-AE6CFF7E-D331-453B-AEE5-2C006A1B1253 wds:Q90005545-B1C9382B-8F3D-423E-8197-1F207784DED3 wds:Q90005545-D851824E-C5A2-4FA2-B32B-74FFE0E530F5
author name string	S A Abdulkadir F J Giles M Cristofanilli R Costa M H Hussain T M Kuzel A Fan J Odegaard B A Carneiro K A Collier R B Lanman R J Nagy S Fairclough S Pamarthy T Taxter Y K Chae
rdfs:label	Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations (en) Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations (nl)
skos:prefLabel	Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations (en) Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations (nl)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software